Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
IMV Inc
IMVIF
Healthcare
Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:IMVIF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 15, 2022 1:35pm
IMV......bounced off the L.O.D
Me no position
(17)
•••
antisense
X
View Profile
View Bullboard History
Comment by
antisense
on Dec 15, 2022 11:22am
RE:INV ....now in PB mode
I mean its a great news release if not LIGHT on details. But probably the worst timing ever as the market as a whole is tanking today (recession fears). IMV can't catch a break here
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 15, 2022 10:37am
INV ....now in PB mode
Has to hold $2.50 u.s and rally or it's over
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 15, 2022 9:48am
IMV ....h.o.d !
Cheers
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 15, 2022 9:44am
IMV.....on watch
trades in Canada & U>S
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 15, 2022 7:06am
New Press Release - IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's)Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitorsOral presentation of the clinical...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 13, 2022 7:05am
New Press Release - IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post...
read article.
(1)
•••
Jthom376
X
View Profile
View Bullboard History
Post by
Jthom376
on Dec 12, 2022 6:57pm
COMPLETE LOSS…
Down 50k... hard way to learn a leason. that group has not integrity. Seen it before but most will work an extension... this group folded, gave no care to the day to day shareholders. And
...more
(2)
•••
europe10
X
View Profile
View Bullboard History
Post by
europe10
on Dec 12, 2022 3:56pm
Game over
10:1 split an financing game over for shareholders
(38)
•••
Hideaway
X
View Profile
View Bullboard History
Comment by
Hideaway
on Dec 09, 2022 3:40pm
RE:RE:a pity
IMV Has been a great disappointment considering what was put forward by management over the years I was a shareholder and what seemed to be very impressive science. After each blunder by management,I
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 07, 2022 4:05pm
New Press Release - IMV Shareholders Approve Reverse Stock Split at 88%
IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and...
read article.
(38)
•••
Hideaway
X
View Profile
View Bullboard History
Comment by
Hideaway
on Dec 06, 2022 3:12pm
RE:a pity
Totally agree,Europe. Successful phase1 for RSV,then let it lapse.Spoke with them several times years ago,but they only wanted to concentrate on cancer as you point out.Never made sense to me.
(2)
•••
europe10
X
View Profile
View Bullboard History
Post by
europe10
on Dec 06, 2022 2:32pm
a pity
It is a pity that IMV held back on the research to find a vaccine against RSV viruses. Covid vaccine trial was a joke but RSV was always there and is once again exploding So many infants in hospital
...more
(2)
•••
europe10
X
View Profile
View Bullboard History
Comment by
europe10
on Dec 06, 2022 2:18pm
RE:SP and Volume
There is a new poster at San Anonio Breast Cancer Symposium. "MVP-S increase Th1 immune respone ......... However, tomorrows decision of reversed split is not going to help the stock I lost all
...more
(38)
•••
Hideaway
X
View Profile
View Bullboard History
Post by
Hideaway
on Dec 06, 2022 1:01pm
SP and Volume
IMV has creeped up a bit in both shares traded and a few cents higher. Any thoughts as to why?
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario